Det lyder jo faktisk temmeligt spændende. Lyder som om Genmab vil prøve at efterligne Novartis strategi med at udvide bredden af de produkter som (forventes at) give overskud og skære alt andet væk. Hvad tænker I andre om denne sag?
Vh Jens
Vh Jens
21/4 2010 16:10 gentogen 0
28392 Det lyder da meget godt, men hvordan hænger det sammen med dette:
Copenhagen, Denmark; April 21, 2010 ? Genmab A/S (OMX: GEN) will announce today at its Annual General Meeting a new pre-clinical antibody program, HuMax-cMet?, as well as a novel next generation bispecific antibody technology.
HuMax-cMet is a fully human IgG1 antibody that targets the cMet oncogenic protein. cMet is the receptor for hepatocyte growth factor, which is over-expressed or shows abnormal activity in a wide variety of solid tumors. HuMax-cMet may have the potential to treat a variety of solid cancers, including breast, lung, pancreatic, ovarian, prostate, renal, gastric and colorectal.
HuMax-cMet was selected from a panel of over 75 unique human antibodies. HuMax-cMet targets the cMet protein at a unique site, binding strongly and showing anti-cancer activity in experimental laboratory and animal cancer models. Preparations for filing an IND to begin clinical trials are ongoing.
Bispecific antibodies combine the ability to bind two targets in a single molecule. This may result in more precise targeting and increased efficiency of disease killing mechanisms. Previous generations of bispecific technologies suffered from manufacturing difficulties and/or instability of bispecific molecules and also only remained in the body for a very short period of time. Genmab?s novel proprietary bispecific antibody technology results in efficient generation of the desired type of bispecific antibodies. The new bispecific antibodies are human, stable and may remain in the body as long as regular human antibodies, giving the new bispecific antibodies more time to attack disease.
?We believe HuMax-cMet has great potential as a treatment for cancer. We also believe this novel antibody technology will further catalyze the development of novel antibody therapeutic approaches for cancer and other debilitating diseases,? Said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.
Copenhagen, Denmark; April 21, 2010 ? Genmab A/S (OMX: GEN) will announce today at its Annual General Meeting a new pre-clinical antibody program, HuMax-cMet?, as well as a novel next generation bispecific antibody technology.
HuMax-cMet is a fully human IgG1 antibody that targets the cMet oncogenic protein. cMet is the receptor for hepatocyte growth factor, which is over-expressed or shows abnormal activity in a wide variety of solid tumors. HuMax-cMet may have the potential to treat a variety of solid cancers, including breast, lung, pancreatic, ovarian, prostate, renal, gastric and colorectal.
HuMax-cMet was selected from a panel of over 75 unique human antibodies. HuMax-cMet targets the cMet protein at a unique site, binding strongly and showing anti-cancer activity in experimental laboratory and animal cancer models. Preparations for filing an IND to begin clinical trials are ongoing.
Bispecific antibodies combine the ability to bind two targets in a single molecule. This may result in more precise targeting and increased efficiency of disease killing mechanisms. Previous generations of bispecific technologies suffered from manufacturing difficulties and/or instability of bispecific molecules and also only remained in the body for a very short period of time. Genmab?s novel proprietary bispecific antibody technology results in efficient generation of the desired type of bispecific antibodies. The new bispecific antibodies are human, stable and may remain in the body as long as regular human antibodies, giving the new bispecific antibodies more time to attack disease.
?We believe HuMax-cMet has great potential as a treatment for cancer. We also believe this novel antibody technology will further catalyze the development of novel antibody therapeutic approaches for cancer and other debilitating diseases,? Said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.
21/4 2010 22:47 JensH 028401 Ja... du har en pointe.
Lad mig lige starte forfra på mit spørgsmål: Hvad i alverden betyder denne pressemeddelelse i realiteten?
Lad mig lige starte forfra på mit spørgsmål: Hvad i alverden betyder denne pressemeddelelse i realiteten?
hej jensh, det er svært at sige, mit klare indtryk er at de skærer meget ned i klinikken, som også er sammenfalende med at de er helt nede på 220 medarbejdere.
23/4 2010 14:34 gentogen 028468 Selv om cMet ser spændende ud, så har det jo også lange udsigter. Det virker vel sådan lidt i retning af, at ledelsen ville være sikre på at have mindst en positiv historie at fortælle til generalforsamlingen. At den europæiske godkendelse lige akkurat nåede at komme før d. 21/4, kunne de jo ikke vide på forhånd.
